# Cancer Risk in People Without Diabetes

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/cancer-risk-in-people-without-diabetes

> A study in obese adults without diabetes found 41% lower incidence of obesity-associated cancers. The median follow-up was two years, far too short to establish that a drug prevented anything.

## Key points

- HR 0.59 (95% CI 0.53–0.67) for obesity-associated cancers, in nondiabetic adults.
- Median follow-up two years, so a cancer found in that window was, in most cases, already there.
- Studying people without diabetes removes the sicker-comparator confound that wrecks other studies.
- The one subgroup that differed points at access and screening, not biology.

Most studies of these drugs and cancer are done in people with diabetes, where the comparison drug is itself a marker of how sick someone is. This one was done in obese adults **without** diabetes, and found 41% lower incidence of obesity-associated cancers.[1] It also has a median follow-up of two years, which is the problem.

## What was found

After propensity score matching, GLP-1 users had a significantly lower incidence of obesity-associated cancers, with a hazard ratio of **0.59** (95% CI 0.53 to 0.67). Participants had a mean age of 47.2. An inverse probability of treatment weighting analysis confirmed the finding, and it held across subgroups, with one exception discussed below.[1]

The population is what this study adds. We have written about a study reporting 91% lower breast cancer mortality that [evaporated against a fair comparator](https://glpwatchdog.org/research/glp1-and-cancer-risk-what-the-cohorts-show), because insulin users are sicker than GLP-1 users by definition. Studying people without diabetes removes that specific problem.

## Two years is not long enough to answer this

> A cancer diagnosed within two years of starting a drug was, in most cases, already there when the drug started.

Solid tumors develop over years to decades. A median follow-up of two years, with an interquartile range of one to two, captures diagnoses rather than causation. The authors describe the result as a *short-term* incidence finding and call for prospective trials to confirm causality.[1]

This is the same structural limitation we found in the randomized evidence: a systematic review in the Annals of Internal Medicine concluded that any effect of these drugs on obesity-related cancers may be little or none, while noting the included trials *were not designed to evaluate cancer outcomes and had short follow-up*. That is in [the randomized answer](https://glpwatchdog.org/research/glp1-cancer-risk-the-randomized-answer).

> **There is a mechanism that could produce this result with no anti-cancer effect at all.** People who start a new prescription drug enter the health system: appointments, bloodwork, imaging for other reasons. Detection patterns differ between people receiving active treatment and people who are not, in both directions, and a two-year window is exactly where a detection difference would dominate a biological one.

## The subgroup that did not follow the pattern

The association held in every subgroup examined **except Black patients**.[1] The careful reading of that finding is not a biological one.

We covered the same shape in [who responds in the real world](https://glpwatchdog.org/research/who-responds-in-the-real-world), where a real-world cohort found weight-loss outcomes differing by race while 64 randomized trials found none. The explanation there applies here: trials equalize access, continuity and follow-up, and ordinary care does not. A benefit that requires sustained treatment will appear smaller in any group whose treatment is more often interrupted. A benefit measured by *diagnosis* also depends on who receives screening.

Reading a subgroup difference in an observational cancer study as a difference in how bodies respond, rather than in how care is delivered, would be unsupported by the randomized evidence and would mislocate the problem.

## Where this leaves the question

- **The direction is consistent** across cohorts, drug classes and now a nondiabetic population, which carries some weight.
- **The magnitude is not.** A 41% reduction is large enough to trigger the rule we set out in [when a hazard ratio is too good](https://glpwatchdog.org/research/when-a-hazard-ratio-is-too-good): in observational data, big effects usually describe who was prescribed the drug.
- **The mechanism is plausible.** Obesity is an established driver of the thirteen cancer types usually classed as obesity-associated, and these drugs reduce obesity.
- **The follow-up cannot support the claim.** Two years is too short to answer this question, whatever result it shows.

Nothing here is a reason to take or avoid one of these drugs on cancer grounds, and no GLP-1 is indicated for cancer prevention anywhere.

## Frequently asked questions

### Do GLP-1 drugs reduce cancer risk in people without diabetes?

A large propensity-matched study found 41% lower short-term incidence of obesity-associated cancers, with a hazard ratio of 0.59. The median follow-up was two years, which is far too short to establish that a drug prevented a cancer.

### Why does studying people without diabetes matter?

Because most cancer studies in this class compare against other diabetes drugs, and drugs like insulin mark more advanced disease. Comparing against them measures how sick each group already was. A nondiabetic population removes that particular confound.

### Why is two years too short?

Solid tumors develop over years to decades, so a cancer diagnosed within two years of starting a drug was, in most cases, present beforehand. The authors themselves describe this as a short-term incidence finding and call for prospective trials.

### What about the finding in Black patients?

The association held in every subgroup except Black patients. The supported reading is about care, not biology. A benefit requiring sustained treatment appears smaller in any group whose treatment is more often interrupted, and a benefit measured by diagnosis depends on who receives screening.

### Should anyone take one to prevent cancer?

No. There is no such indication anywhere, the follow-up in this study cannot support a causal claim, and randomized evidence to date suggests little or no effect either way.

## References

1. Hsu AH, Ramirez PT, Chang YH, et al. GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults. Annals of Oncology. 2026. PMID: 42252247. https://pubmed.ncbi.nlm.nih.gov/42252247/

---

Cite as: GLP Watchdog, Nora Bissett, "Cancer Risk in People Without Diabetes", published 2026-08-20, updated 2026-11-02. https://glpwatchdog.org/research/cancer-risk-in-people-without-diabetes

Canonical HTML page: https://glpwatchdog.org/research/cancer-risk-in-people-without-diabetes

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
